AGAThe Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology
Abbreviations
Cited by (0)
This article is being published jointly in 2012 in Gastroenterology, American Journal of Gastroenterology, and Hepatology.
Potential Conflicts of Interest Naga Chalasani, MD, FACG has received compensation for providing consulting related to NAFLD and NASH from Amylin, Gilead, Genentech, and Mochida and he has received research support from Amylin, Eli Lilly, Intercept, and Cumberland Pharmaceuticals in the last 3 years. Over the last 3 years, he has received compensation for providing consultation related to drug hepatotoxicity from J & J, Merck, GlaxoSmithKline, Karo Bio, Salix, Advanced Life Sciences, BMS, Teva Pharmaceuticals, Abbott, Biolex, Sanofi-Aventis, and Vertex.
Zobair Younossi, MD has received consulting fees from Salix, Tibotec, and Vertex.
Anna Mae Diehl, MD has received compensation for providing consulting related to NAFLD from Vertex, Norgine, and Celgene.
Elizabeth Brunt, MD has received compensation from Amylin, Pfizer, and Geneva Foundation for NASH consulting.
Kenneth Cusi, MD has received compensation from Merck, Daichi-Sankyo, and Roche for providing consulting.
Michael Charlton, MD has received compensation from Gilead and Genentech for providing consulting related to NAFLD and NASH.
Joel Lavine, MD, PhD has received compensation for providing consultations related to NAFLD from Quark Pharmaceuticals and Synageva BioPharma, and received research support from Raptor Pharmaceuticals, all in the last 3 years.
Arun Sanyal, MD has served as an ad hoc advisor to Roche, Takeda, Merck, Astella, Sanofi, Exhalenz, and Immuron. He serves as the global PI for trials for Exhalenz and Immuron.